华北制药：获得腺苷钴胺胶囊的《药品注册证书》

Core Viewpoint - North China Pharmaceutical (600812.SH) has received the drug registration certificate for Adenosylcobalamin capsules (0.5mg) from the National Medical Products Administration, indicating the product's compliance with basic procurement bidding conditions and its efficacy equivalent to the original product [1] Group 1: Product Approval and Market Impact - The newly approved product is primarily used for the prevention and treatment of Vitamin B12 deficiency, which is increasingly needed due to insufficient dietary intake, as well as for megaloblastic anemia [1] - The approval enhances the company's product pipeline in blood and hematopoietic system medications, filling a gap in their offerings [1] Group 2: Industry Considerations - The sales of formulation products are subject to uncertainties due to potential changes in domestic pharmaceutical industry policies and market environment [1]